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Background: Structural follow-up magnetic resonance imaging (MRI) after stereotactic radiosurgery (SRS) for brain
metastases frequently displays local changes in the area of applied irradiation, which are often difficult to interpret
(e.g., local tumor recurrence, radiation-induced changes). The use of stereotactic biopsy for histological assessment
of these changes has a high diagnostic accuracy and can be considered as method of choice. In order to solve this
relevant clinical problem non-invasively, advanced MRI techniques and amino acid positron-emission-tomography
(PET) are increasingly used.
Case presentation: We report the long-term follow-up of a patient who had been treated with linear accelerator
based SRS for cerebral metastases of a lung cancer. Fifty-eight months after SRS, the differentiation of local recurrent
brain metastasis from radiation-induced changes using structural MRI was difficult. For further differentiation, perfusion-
weighted MRI (PWI), proton magnetic resonance spectroscopy (MRS), and 11C-methyl-L-methionine (MET) PET was
performed. Due to artifacts and technical limitations, PWI MRI and MRS findings were not conclusive. In contrast, MET
PET findings were suggestive for radiation-induced changes. Finally, a stereotactic biopsy for histological assessment of
these changes demonstrated clearly a radiation-induced necrosis and the absence of vital tumor.
Conclusion: The use of stereotactic biopsy for histological assessment of indistinguishable lesions on structural MRI
after SRS for treatment of brain metastasis represents a highly reliable method to differentiate local tumor recurrence
from radiation-induced changes. In this field, results of studies with both advanced MRI techniques and amino acid PET
suggest encouraging results. However, artifacts and technical limitations (e.g., lesion size) are still a problem and
comparative studies are needed to investigate the relationship, diagnostic performance, and complementary character
of advanced MRI techniques and amino acid PET.
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Early detection of brain metastasis provided by advanced
screening programs as well as improvements of treat-
ment in general oncology is positively influencing the
course of the disease and overall survival of patients with
brain metastases. To date, the use of stereotactic radio-
surgery (SRS) is a widely accepted treatment option for
(singular) cerebral metastasis [1-3]. As a consequence,
the appearance of local signal changes on follow-up MRI
in the irradiated region is observed in up to 22% of cases
after SRS [4]. The interpretation of findings of structural
magnetic resonance imaging (MRI) at follow-up after
treatment with SRS (i.e., changing patterns of contrast
enhancement and alterations of T2-/FLAIR-weighted
images) is difficult or even impossible in order to differ-
entiate local tumor recurrence from radiation-induced
changes [5-8]. Furthermore, little experience is reported
whether and when these changes occur in patients dur-
ing long-term follow-up.
We present a follow-up of more than 5 years of a pa-
tient after treatment of cerebral metastases using SRS.
During follow-up, the assignment of structural MRI
changes to local tumor recurrence or radiation-induced
changes was difficult. Regarding this clinically relevant
issue, we discuss noninvasive advanced imaging methods
based on MRI (i.e., perfusion-weighted MRI (PWI), pro-
ton magnetic resonance spectroscopy (MRS), and
positron-emission-tomography (PET)).Figure 1 Contrast-enhanced MR images during the course of the dise
contrast enhancement recurs within the area of applied irradiation. A differ
not possible.Case presentation
In November 2005, in a 58-year-old male patient an
adenocarcinoma of the lung was diagnosed and he
underwent multimodal treatment including resection of
the upper pulmonary lobe and adjuvant chemotherapy.
Nine months later (July 2006), a follow-up MRI revealed
a contrast-enhancing solitary lesion in the left frontal
brain, highly suggestive for a brain metastasis originating
from adenocarcinoma of the lung (Figure 1). The lesion
was treated by linear accelerator (LINAC) based SRS
(tumor volume, 0.6 ml; surface dose, 20 Gy; isodose level,
65%) [9,10]. Follow-up MRI after 3 months (Figure 1)
showed a decrease of contrast enhancement > 50% of the
treated lesion (partial response according to the Macdonald
criteria [11]) as well as a new enhancing lesion also sug-
gestive for a metastasis in the left temporal lobe (Figure 1),
which was also treated with LINAC based SRS (tumor vol-
ume, 1.2 ml; surface dose, 20 Gy; isodose level, 65%). The
subsequent MRI performed in December 2006 showed
complete remission of both metastases (images not
shown).
Thirty-seven months after SRS of the left temporal
metastasis, a new contrast-enhancing lesion with pe-
rifocal edema was detected in the area of applied irradi-
ation (Figure 1). Due to further progression of size in
the follow-up MRI one month later (tumor volume,
2.8 ml), the lesion was highly suspicious for local tumor
recurrence. In order to differentiate local tumorase. Fifty-eight months after LINAC SRS of the left frontal metastasis,
entiation of local tumor recurrence from radiation-induced changes is
Figure 2 Multimodal imaging with structural MRI (contrast-enhanced T1- and FLAIR-weighted sequence), PWI MRI, and MET PET at the
time point of suspected tumor recurrence. PWI MRI shows a perfusion deficit, areas with increased relative cerebral blood volume (rCBV) are
not present. In contrast, MET PET is suggestive for radiation-induced changes (mean tumor-to-brain ratio, 1.40).
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tic biopsy was performed. Histological assessment re-
vealed a radiation-induced necrosis. Tumor cells were
completely absent. The diagnosis of a radiation-induced
necrosis was additionally confirmed by the clinical andFigure 3 Spectroscopic profile of the left frontal lesion (red voxel), altradiological course. In follow-up MR imaging, the con-
trast enhancement vanished completely (Figure 1).
Fifty-eight months after SRS of the left frontal metastasis,
we observed a recurrence of contrast enhancement (tumor
volume, 1.8 ml) within the area of applied irradiationered by artifacts.
Figure 4 Histology of left frontal tissue, obtained by
stereotactic biopsy. Hyalinized radiation-induced necrosis, H&E
staining, original magnification x100. Within the necrosis, blood
vessels with thickened walls and obturated lumen (dotted arrow).
On the left side, vital brain parenchyma with hemosiderin
deposits (arrows).
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MRI (Figure 1, 2). For further evaluation of this lesion,
PWI MRI, MRS, and 11C-methyl-L-methionine (MET)
PET was performed.
In detail, PWI MRI revealed a perfusion deficit with
low mean transit time and low relative cerebral blood
volume (rCBV), which was corresponding to the signal
alterations on the FLAIR-weighted image (Figure 2).
Areas with increased rCBV, however, could not be
clearly identified within the perfusion deficit. Further-
more, diagnostic information of MRS was heavily
influenced by artifacts and was therefore inconclusive
(Figure 3). It should be noted that most probably due to
the patient’s unusual large frontal sinus adjacent to the
left frontal lesion, the diagnostic value of PWI MRI, and
MRS might have been negatively influenced. MET PET
imaging of the suspicious left frontal lesion revealed a
mean tumor-to-brain ratio of 1.40 (normalized against
the gray matter of the unaffected right frontal cortex)
(Figure 2). It has been previously demonstrated that a
mean threshold of at least 1.41 or 1.42 has the best diag-
nostic accuracy for the identification of recurrent brain
metastasis [12,13]. Accordingly, the tumor-to-brain ratio
of 1.40 was suggestive for radiation-induced necrosis.
Nevertheless, the ratio of 1.40 was very close to the
thresholds for diagnosis of recurrent metastasis (1.41
and 1.42, respectively) and MR imaging findings were
not helpful. We therefore decided to perform a stereo-
tactic biopsy for histological evaluation of the suspicious
left frontal lesion. According to our previously reported
protocol, a stereotactic 125I brachytherapy (SBT) after
intraoperative verification of tumor within the same sur-
gical procedure was planned [6,14]. Intraoperatively,
histological findings were consistent with radiation ne-
crosis (Figure 4). Thus, SBT was not performed.
Follow-up MRI after 74 months showed a decrease of
contrast enhancement (Figure 1). During the complete
course of the disease, the patient was asymptomatic and
had no neurological deficit. Furthermore, there were no
clinical signs for systemic disease progression.
Conclusions
To date, contrast-enhanced structural MRI is the
method of choice for follow-up of brain metastasis after
treatment with SRS. However, in many patients, the dif-
ferentiation of local recurrent brain metastasis from
radiation-induced changes after SRS using contrast-
enhanced MRI is difficult [15]. This problem necessitates
alternative diagnostic methods for the follow-up and
management of patients with recurrent brain metastases.
Various imaging techniques such as PET, single-photon
emission computed tomography (SPECT), MRS, and
PWI have been used for differentiation of local tumor
recurrence from radiation-induced changes (Table 1).PET using 2-deoxy-[18F]fluoro-D-glucose (FDG) [26]
has been considered for the evaluation of brain metasta-
sis, but the high physiologic glucose consumption of the
brain and the variable glucose uptake of metastatic brain
lesions limit its use. For example, in a study of 48 pa-
tients with lung cancer and brain metastasis, 33% of the
brain lesions could not be clearly detected by FDG PET,
although all primary lung lesions were hypermetabolic
[27]. Furthermore, another limitation is a small lesion
size [28]. Another study demonstrated that after SRS,
FDG PET is not sensitive enough to differentiate brain
metastases from radiation necrosis [20]. Additionally,
the diagnostic accuracy of FDG PET may be negatively
influenced since it could be observed that FDG uptake is
also seen in inflammatory changes [29]. A recent study
indicated that dual-phase imaging may improve the
diagnostic accuracy of FDG PET for the differentiation
of recurrent brain metastasis from radiation necrosis
Table 1 Diagnostic value of several imaging techniques in differentiating tumor recurrence from radiation necrosis after SRS for brain metastases
Study Imaging modality Number of patients
(metastasis)
Treatment (n) Interval SRS –
Imaging (mo)






Serizawa et al., 2005 [16] 201Thallium SPECT 70 (72) SRS 7 30/42 10 62 90% 91%
Tsuyuguchi et al., 2003 [12] MET PET 21 (21) SRS 12 9/12 11 10 78% 100%
Terakawa et al., 2008 [13] MET PET 51 (56) SRS (47), EBI (4) 17 24/32 56 0 79% 75%
Galldiks et al., 2012 [17] FET PET 31 (40) SRS (16), SRS+WBRT (15) 12 19/21 11 29 95% 91%
Horky et al., 2010 [18] Dual phase FDG PET 25 (27) SRS/EBI (22), CTx (3) 18,15 n.r. 16 11 95% 100%
Chao et al., 2001 [19] FDG PET 32 (36) SRS 6 18/18 n.r. n.r. 65% 80%
FDG PET + MRI 32 (36) SRS 6 18/18 n.r. n.r. 86% 80%
Belohlavek et al., 2003 [20] FDG PET 25 (57) SRS 8 8/49 3 54 75% 94%
Chernov et al., 2005 [21] FDG PET 9 (9) SRS 11 4/5 5 4 50% 80%
Single voxel MRS 9 (9) SRS 11 4/5 5 4 50% 100%
Multi voxel MRS 9 (9) SRS 11 4/5 5 4 100% 100%
Kimura et al., 2003 [22] Single voxel MRS 36 (43) SRS 6-12 0/6 5 1 100%*
Barajas et al., 2009 [23] PWI 27 (30) SRS 10 20/10 22 8 96% 100%
Hoefnagels et al., 2009 [4] PWI 31 (34) SRS 8/9 20/14 11 23 70% 100%
Mitsuya et al., 2010 [24] PWI 27 (28) SRS 12 7/21 2 26 100% 95%
Truong et al., 2006 [25] PWI 12** SRS 9 10/2 12 0 PPV 80%
Multi voxel MRS 9*** SRS 9 7/2 9 0 PPV 83%
*Radiation necrosis was correctly diagnosed in all cases; **3 patients were excluded due to susceptibility artifacts; ***2 patients were excluded.
CTx = chemotherapy; PWI = perfusion weighted imaging; EBI = external beam irradiation; FDG = 2-deoxy-[18F]fluoro-D-glucose; FET = O-(2-18F-Fluoroethyl)-L-tyrosine; FLAIR = fluid attenuated inversion recovery;
FU = confirmation of diagnosis by (serial) follow-up MRI; Histo = diagnosis proven by histological confirmation; MET = 11C-methyl-L-methionine; MRS = magnetic resonance spectroscopy; n.r. = not reported;
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time interval between PET scans (range, 2–5.7 h).
Amino acid tracers are particularly useful for PET in
Neurooncology because of a high amino acid uptake in
tumor tissue both in metastasis and gliomas [30] to-
gether with low uptake in normal brain tissue, resulting
in an enhanced tumor-to-background contrast. Previ-
ously, it has been shown that PET using MET may be ef-
fective in differentiating recurrent metastatic brain
tumor from radiation-induced changes (at a threshold of
1.42, mean tumor-to-brain ratio) with a sensitivity of
78% and a specificity of 100%, respectively [12]. In a sub-
sequent study [13], these findings could be confirmed at
a similar threshold (1.41, mean tumor-to-brain ratio), at
least in part, with similar sensitivity (79%) but with lower
specificity (75%). Following these thresholds (1.41 and
1.42, respectively), the mean tumor-to-brain ratio of 1.40
of the left frontal lesion in our patient was suggestive for
radiation-induced changes. However, this ratio was very
close to the reported thresholds for diagnosis of recur-
rent metastasis and might therefore cause several con-
cerns regarding the correct diagnosis. For example, the
calculated mean tumor-to-brain ratio may slightly vary
depending on the choice of the background region-of
-interest (ROI). It should be noted that the use of MET
remains restricted to centers with an on-site cyclotron
because of the short half-life of the 11C isotope (20 min).
In contrast, amino acids labeled with 18F (half-life,
110 min) such as O-(2-18F-fluoroethyl)-L-tyrosine (FET)
allow a more widespread use. In a recent study it could
be demonstrated that the combination of the mean
tumor-to-brain ratio and FET kinetics helps to differen-
tiate recurrent brain metastasis tumor from radiation-
induced changes with a high diagnostic accuracy [17].
A study with 201Thallium SPECT provided the correct
diagnosis of recurrent brain metastasis with a sensitivity
of 90% and specificity of 92%, respectively [16]. However,
the spatial resolution of SPECT is considerably lower
than that of PET, which limits the use of this technique
in clinical practice.
Beyond structural MR imaging, advanced MRI tech-
niques such as PWI and MRS can be used successfully
in order to differentiate recurrent brain metastasis from
radiation-induced changes. Especially PWI can be easily
incorporated into daily practice since the acquisition
time is short (less than 10 minutes) [31]. In this context,
the diagnostic value of PWI and MRS has been investi-
gated by several studies [4,23-25,32]. In these studies,
the sensitivity of PWI MRI ranged from of 70–100% and
the specificity from 95–100%, respectively. Chernov and
colleagues reported a sensitivity and specificity of 100%
using MRS in pilot series of 9 patients [21]. However, it
should be noted that these promising results of studies
with advanced MRI techniques are mostly based on alimited number of patients investigated predominantly
in a retrospective setting, without histological confirm-
ation of the diagnosis.
In addition, all of the latter mentioned MR-based tech-
niques can be influenced negatively by technical limita-
tions. For example, a small size or irregular shape of the
lesion might affect negatively the data analysis. Inappro-
priate ROI placement (e.g., in heterogeneous lesions with
cystic and necrotic regions) and partial volume effects
may alter results. Furthermore, susceptibility artifacts
due to air-containing and bony structures (e.g., sinuses,
temporal bone) adjacent to the lesion may hinder data in-
terpretation and analysis [25,33]. Additionally, for assess-
ment of small lesions (< 2 ml) using MRS, the signal-to
-noise ratio becomes a limiting factor requiring examin-
ation times inapplicable for clinical use [34]. In a previous
study, the rate of unusable MRS examinations due to mo-
tion artifacts was about 7% [35].
Regarding the reported patient, susceptibility artifacts
and the small lesion size most probably caused the in-
conclusive findings of PWI MRI and MRS. In contrast,
MET PET indicated radiation-induced changes within
its limits of the previously described diagnostic accuracy.
Ultimately, a stereotactic biopsy demonstrated clearly
the absence of vital tumor. Stereotactic biopsy is a highly
reliable diagnostic method for differentiating local tumor
recurrence from radiation necrosis. Two prospective
studies demonstrated the usefulness of this procedure to
deliver conclusive results with a high diagnostic accuracy
of more than 98% and a low risk (< 1%) of permanent
complications [36,37]. Although this procedure is re-
stricted to specialized institutions, stereotactic biopsies
can be considered as method of choice, especially when
diagnostic information derived from noninvasive im-
aging techniques are inconclusive.
In conclusion, artifacts and technical limitations of ad-
vanced MRI techniques can be a relevant problem and,
furthermore, comparative studies are needed to investi-
gate the relationship, diagnostic performance, and com-
plementary character of advanced MRI techniques and
amino acid PET. Results of multimodal imaging studies
should be evaluated by stereotactic biopsy.
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